Yu AL - Search Results

1

KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.

Erbe AK, Diccianni MB, Mody R, Naranjo A, Zhang FF, Birstler J, Kim K, Feils AS, Hung JT, London WB, Shulkin BL, Mathew V, Parisi MT, Servaes S, Asgharzadeh S, Maris JM, Park J, Yu AL, Sondel PM, Bagatell R. Erbe AK, et al. Among authors: yu al. J Immunother Cancer. 2023 Feb;11(2):e006530. doi: 10.1136/jitc-2022-006530. J Immunother Cancer. 2023. PMID: 36822669 Free PMC article.

2

Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia.

Diccianni MB, Yu J, Hsiao M, Mukherjee S, Shao LE, Yu AL. Diccianni MB, et al. Among authors: yu al, yu j. Blood. 1994 Nov 1;84(9):3105-12. Blood. 1994. PMID: 7949183 Free article.

3

The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance.

Diccianni MB, Chau LS, Batova A, Vu TQ, Yu AL. Diccianni MB, et al. Among authors: yu al. Cancer Lett. 1996 Jul 12;104(2):183-92. doi: 10.1016/0304-3835(96)04250-4. Cancer Lett. 1996. PMID: 8665486

4

Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy.

Batova A, Diccianni MB, Nobori T, Vu T, Yu J, Bridgeman L, Yu AL. Batova A, et al. Among authors: yu al, yu j. Blood. 1996 Oct 15;88(8):3083-90. Blood. 1996. PMID: 8874207 Free article.

5

Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia.

Batova A, Diccianni MB, Yu JC, Nobori T, Link MP, Pullen J, Yu AL. Batova A, et al. Among authors: yu al, yu jc. Cancer Res. 1997 Mar 1;57(5):832-6. Cancer Res. 1997. PMID: 9041181

6

Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions.

Diccianni MB, Batova A, Yu J, Vu T, Pullen J, Amylon M, Pollock BH, Yu AL. Diccianni MB, et al. Among authors: yu al, yu j. Leuk Res. 1997 Jun;21(6):549-58. doi: 10.1016/s0145-2126(97)00007-6. Leuk Res. 1997. PMID: 9279366

7

Frequent deregulation of p16 and the p16/G1 cell cycle-regulatory pathway in neuroblastoma.

Diccianni MB, Omura-Minamisawa M, Batova A, Le T, Bridgeman L, Yu AL. Diccianni MB, et al. Among authors: yu al. Int J Cancer. 1999 Jan 5;80(1):145-54. doi: 10.1002/(sici)1097-0215(19990105)80:1<145::aid-ijc26>3.0.co;2-g. Int J Cancer. 1999. PMID: 9935245

8

Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro.

Batova A, Diccianni MB, Omura-Minamisawa M, Yu J, Carrera CJ, Bridgeman LJ, Kung FH, Pullen J, Amylon MD, Yu AL. Batova A, et al. Among authors: yu al, yu j. Cancer Res. 1999 Apr 1;59(7):1492-7. Cancer Res. 1999. PMID: 10197619

9

The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.

Batova A, Kamps A, Gillies SD, Reisfeld RA, Yu AL. Batova A, et al. Among authors: yu al. Clin Cancer Res. 1999 Dec;5(12):4259-63. Clin Cancer Res. 1999. PMID: 10632368

10

Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia.

Omura-Minamisawa M, Diccianni MB, Batova A, Chang RC, Bridgeman LJ, Yu J, Pullen J, Bowman WP, Yu AL. Omura-Minamisawa M, et al. Among authors: yu al, yu j. Clin Cancer Res. 2000 Apr;6(4):1219-28. Clin Cancer Res. 2000. PMID: 10778944

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

305 results

Search Page

Filters